Oral News and Research

RSS

Transplantation conditioning choices impact on CML outcomes revealed

For chronic myeloid leukaemia patients in their first chronic phase, the optimal pretransplantation conditioning regimen may be cyclophosphamide combined with intravenous busulfan, research suggests.

17 Feb 2015

ASU to host inaugural meeting for brand new scientific society in Tempe, Arizona

Arizona State University will host a premiere opportunity to engage and mingle with luminaries in the burgeoning field of evolutionary medicine, a new interdisciplinary approach that is becoming an essential perspective in our view of disease, today's medical practice and the worldwide impact on public health as it hosts the Inaugural International Society for Evolution, Medicine & Public Health Meeting, March 19-21, 2015 in Tempe, Arizona.

17 Feb 2015

Medical practitioners rarely prescribe proper treatments for childhood diarrhea, pneumonia in rural India

Few health care providers in rural India know the correct treatments for childhood diarrhea and pneumonia - two leading killers of young children worldwide. But even when they do, they rarely prescribe them properly, according to a new Duke University study.

16 Feb 2015

Study: Ebola transmission from deceased patients may be possible

To determine how long Ebola virus could remain infectious in a body after death, National Institutes of Health scientists sampled deceased Ebola-infected monkeys and discovered the virus remained viable for at least seven days. They also detected non-infectious viral RNA for up to 70 days post-mortem. The study, published in Emerging Infectious Diseases, suggests that Ebola transmission from deceased individuals may be possible for an extended period of time following death, underscoring the importance of using safe practices for handling corpses.

15 Feb 2015

Risk of ovarian cancer increased with even short-term HRT use

There has been much uncertainty regarding the risk of cancer associated with taking hormone replacement therapy (HRT) for the menopause. An analysis of all available evidence published in The Lancet today shows that HRT, even when taken for only a few years, significantly increases the risk of developing the two most common types of ovarian cancer.

13 Feb 2015

Jazz Pharmaceuticals to present defibrotide results for hepatic VOD at BMT Tandem meetings

Jazz Pharmaceuticals plc announced today that researchers will present data on the use of defibrotide, an investigational medicine being studied in the United States (U.S.) for the treatment of hepatic veno-occlusive disease (VOD), a rare, potentially life-threatening, early complication in patients undergoing hematopoietic stem-cell transplantation (HSCT) therapy.

13 Feb 2015

Study shows how cannabidiol works within cells

A team of Stony Brook University researchers have identified fatty acid binding proteins (FABPs) as intracellular transporters for two ingredients in marijuana, THC and CBD (cannabidiol).

13 Feb 2015

Analytical strategies that support OSD formulation: A new whitepaper from Malvern Instruments

A new whitepaper from Malvern Panalytical provides detailed guidance on the analytical technologies that help to accelerate oral solid dosage (OSD) product formulation to a successful conclusion.

From Malvern Panalytical 12 Feb 2015

$Lenvatinib therapy improves survival in patients with advanced radioiodine-refractory thyroid cancer$

Lenvatinib therapy improves survival in patients with advanced radioiodine-refractory thyroid cancer

In a pivotal Phase III study led by researchers at The University of Texas MD Anderson Cancer Center, the oral anti-angiogenic therapy lenvatinib has shown dramatic improvement in progression-free survival in patients with advanced radioiodine-refractory thyroid cancer.

12 Feb 2015

Oral pathogen protects different tumor cells from being killed by immune cells

Bacteria that are commonly found in the mouth are often abundant in patients with colon cancer, but the potential role these microbes play in tumor development has not been clear. A study published by Cell Press February 18th in the journal Immunity reveals that the oral pathogen Fusobacterium nucleatum protects a variety of tumor cells from being killed by immune cells.

12 Feb 2015

Experts gather at Cardiology 2015 conference to discuss challenges in treating congenital heart disease

Many aspects of pediatric cardiology are relatively new to the discipline. Only recently have physicians been able to accurately diagnose and characterize the myriad congenital cardiovascular conditions that occur and begin to apply successful strategies for care. This week, an international group of more than 800 medical experts gather at the nation's largest pediatric cardiology conference to discuss challenges in treating congenital heart disease in the fetus, neonates, children and young adults.

12 Feb 2015

Experts to discuss challenges in CHD treatments at pediatric cardiology conference

12 Feb 2015

AbbVie submits NDA in Japan for investigational, all-oral treatment of patients with chronic HCV infection

AbbVie (NYSE: ABBV) submitted a New Drug Application (NDA) to the Japanese Ministry of Health, Labour and Welfare (MHLW) seeking approval for the company's investigational, all-oral, ribavirin (RBV) and interferon (IFN)-free, 12-week, two direct-acting antiviral treatment of ombitasvir/paritaprevir/ritonavir (OBV/PTV/r), dosed once daily.

12 Feb 2015

Cumberland initiates clinical development of Boxaban (ifetroban) oral capsule for AERD treatment

Cumberland Pharmaceuticals Inc. today announced an expansion of its pipeline with a new Phase II development program. The Company has initiated the clinical development of Boxaban (ifetroban) oral capsule for the treatment of aspirin-exacerbated respiratory disease (AERD).

11 Feb 2015

Study shows low-dose oral iron supplementation after blood donation reduces hemoglobin recovery time

Among blood donors with normal hemoglobin levels, low-dose oral iron supplementation, compared with no supplementation, reduced the time to recovery of the postdonation decrease in hemoglobin concentration in donors with low or higher levels of a marker of overall iron storage (ferritin), according to a study in the February 10 issue of JAMA.

11 Feb 2015

Creatine monohydrate fails to slow clinical progression of Parkinson's disease

Treatment with creatine monohydrate for at least 5 years for patients with early and treated Parkinson disease failed to slow clinical progression of the disease, compared with placebo, according to a study in the February 10 issue of JAMA.

11 Feb 2015

Synthetic Biologics reports positive results from SYN-004 Phase 1b trial to prevent C. difficile infection

Synthetic Biologics, Inc., a developer of pathogen-specific therapies for serious infections and diseases, with a focus on protecting the microbiome, today announced positive topline safety and tolerability results from a Phase 1b clinical trial of SYN-004, the Company's investigational oral beta-lactamase enzyme designed to protect the microbiome and prevent Clostridium difficile (C. difficile) infection, antibiotic-associated diarrhea and secondary antibiotic-resistant infections in patients receiving intravenous (IV) beta-lactam antibiotic therapy.

10 Feb 2015

Chiasma announces publication of octreotide capsules Phase III study results in JCEM

Chiasma Inc., a U.S. privately-held biopharma company, announced today that results from a multicenter Phase III study of the investigational new drug, octreotide capsules, were published online for early release on Feb. 9, ahead of print, by the Journal of Clinical Endocrinology & Metabolism.

10 Feb 2015

FDA accepts NDA filing for Inspirion Delivery Technologies' investigational drug, MorphaBond ER

Inspirion Delivery Technologies, LLC, a specialty pharmaceutical company focused solely on the development of Abuse-Deterrent Formulations (ADFs) of opioid products, together with its financial partner Trygg Pharma Group, announced that the U.S. Food & Drug Administration has accepted for filing the New Drug Application ("NDA") submitted on November 21, 2014 for its investigational drug, MorphaBond ER, an extended-release (ER), abuse-deterrent formulation of morphine.

10 Feb 2015

Regulus Therapeutics reports top-line results from RG-101 clinical study for HCV treatment

Regulus Therapeutics Inc., a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, today announced top-line results from the 4 mg/kg cohort and additional results from the 2 mg/kg cohort in a completed clinical study evaluating RG-101, a wholly-owned, GalNac-conjugated anti-miR targeting microRNA-122 ("miR-122"), for the treatment of hepatitis C virus infection ("HCV").

9 Feb 2015

Oral News and Research

Transplantation conditioning choices impact on CML outcomes revealed

ASU to host inaugural meeting for brand new scientific society in Tempe, Arizona

Medical practitioners rarely prescribe proper treatments for childhood diarrhea, pneumonia in rural India

Study: Ebola transmission from deceased patients may be possible

Risk of ovarian cancer increased with even short-term HRT use

Jazz Pharmaceuticals to present defibrotide results for hepatic VOD at BMT Tandem meetings

Study shows how cannabidiol works within cells

Analytical strategies that support OSD formulation: A new whitepaper from Malvern Instruments

Lenvatinib therapy improves survival in patients with advanced radioiodine-refractory thyroid cancer

Oral pathogen protects different tumor cells from being killed by immune cells

Experts gather at Cardiology 2015 conference to discuss challenges in treating congenital heart disease

Experts to discuss challenges in CHD treatments at pediatric cardiology conference

AbbVie submits NDA in Japan for investigational, all-oral treatment of patients with chronic HCV infection

Cumberland initiates clinical development of Boxaban (ifetroban) oral capsule for AERD treatment

Study shows low-dose oral iron supplementation after blood donation reduces hemoglobin recovery time

Creatine monohydrate fails to slow clinical progression of Parkinson's disease

Synthetic Biologics reports positive results from SYN-004 Phase 1b trial to prevent C. difficile infection

Chiasma announces publication of octreotide capsules Phase III study results in JCEM

FDA accepts NDA filing for Inspirion Delivery Technologies' investigational drug, MorphaBond ER

Regulus Therapeutics reports top-line results from RG-101 clinical study for HCV treatment

Industry Focus eBook - Cell & Gene Therapy (1st Edition) eBook

Advancing Neuroscience Research Through Collaboration and Patient-Centered Innovation

The impact of vibration on microscopy

How Omics Technologies Are Transforming Biological Research and Drug Discovery

Latest News